B7-h3-targeting antibody, chimeric antigen receptor, and application thereof

WO2026020799A1PCT designated stage Publication Date: 2026-01-29THINKINGBIOMED TECHNOLOGY (BEIJING) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/077877
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-09
Filing Date
2025-02-18
Publication Date
2026-01-29

Smart Images

  • Figure PCTCN2025077877-FTAPPB-I100001
    Figure PCTCN2025077877-FTAPPB-I100001
  • Figure PCTCN2025077877-FTAPPB-I100002
    Figure PCTCN2025077877-FTAPPB-I100002
  • Figure PCTCN2025077877-FTAPPB-I100003
    Figure PCTCN2025077877-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention provides a B7-H3-targeting antibody or an antigen-binding fragment thereof, a chimeric antigen receptor (CAR) fusion protein comprising an antigen-binding domain targeting B7-H3, and an engineered immune cell (such as a CAR-T cell) expressing the CAR fusion protein. The CAR-T cell of the present invention exhibits high affinity and biological activity, with good in vivo and in vitro anti-tumor effects.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-B7H3 chimeric antigen receptor and application thereof

    CN112521512A

  • B7H3 monoclonal antibody group and medical application thereof

    CN113402610A

  • B7-H3 targeting antibody, chimeric antigen receptor and application thereof

    CN118515768A

  • Anti-b7-h3 monoclonal antibody and use thereof in cell therapy

    WO2020063787A1